Tezacaftor (BioDeep_00000229538)

   

human metabolite


代谢物信息卡片


1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide

化学式: C26H27F3N2O6 (520.1821118)
中文名称: 替扎卡托
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(CO)C1=CC2=CC(=C(C=C2N1CC(CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
InChI: InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1

描述信息

C87006 - Pharmacological Chaperone

同义名列表

5 个代谢物同义名

1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide; 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl}cyclopropane-1-carboxamide; Tezacaftor(VX-661); VX-661TEZACAFTOR; Tezacaftor



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Tanvi Patel, Kimberly McBennett, Senthilkumar Sankararaman, Teresa Schindler, Krithika Sundaram, Nori Mercuri Minich, Sindhoosha Malay, Katherine Kutney. Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index. Pediatric pulmonology. 2024 Mar; 59(3):734-742. doi: 10.1002/ppul.26823. [PMID: 38179878]
  • Kevin Lonabaugh, Galvin Li, Rhonda List, Reyna Huang, Amber James, Andrew Barros, Lindsay Somerville, Dana Albon. Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis. Pharmacotherapy. 2024 Mar; 44(3):231-240. doi: 10.1002/phar.2903. [PMID: 38143243]
  • Eunjin Hong, Lisa M Almond, Peter S Chung, Adupa P Rao, Paul M Beringer. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19. Clinical pharmacology and therapeutics. 2022 06; 111(6):1324-1333. doi: 10.1002/cpt.2585. [PMID: 35292968]
  • Brittany A Wright, Natalie K Ketchen, Leah N Rasmussen, Alyssa R Bartels, Sachinkumar B Singh. Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients. Pediatric pulmonology. 2022 03; 57(3):655-657. doi: 10.1002/ppul.25781. [PMID: 34859619]
  • Max C Petersen, Lauren Begnel, Michael Wallendorf, Marina Litvin. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2022 03; 21(2):265-271. doi: 10.1016/j.jcf.2021.11.012. [PMID: 34862121]
  • Katharina Habler, Anne-Sophie Kalla, Michael Rychlik, Mathias Bruegel, Daniel Teupser, Susanne Nährig, Michael Vogeser, Michael Paal. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum. Clinical chemistry and laboratory medicine. 2022 01; 60(1):82-91. doi: 10.1515/cclm-2021-0724. [PMID: 34668357]
  • Vinciane Saint-Criq, Yiting Wang, Livia Delpiano, JinHeng Lin, David N Sheppard, Michael A Gray. Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2021 09; 20(5):843-850. doi: 10.1016/j.jcf.2021.04.013. [PMID: 34020896]
  • Steffie E M Vonk, Marloes van der Meer-Vos, Lieuwe D J Bos, Anne H Neerincx, Christof J Majoor, Anke-Hilse Maitland-van der Zee, Ron A A Mathôt, E Marleen Kemper. Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability. Therapeutic drug monitoring. 2021 08; 43(4):555-563. doi: 10.1097/ftd.0000000000000829. [PMID: 33165217]
  • Patrick G Dougherty, Jack H Wellmerling, Amritendu Koley, Jessica K Lukowski, Amanda B Hummon, Estelle Cormet-Boyaka, Dehua Pei. Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis. Journal of medicinal chemistry. 2020 12; 63(24):15773-15784. doi: 10.1021/acs.jmedchem.0c01528. [PMID: 33314931]
  • Miquéias Lopes-Pacheco, Iris A L Silva, Mark J Turner, Graeme W Carlile, Elvira Sondo, David Y Thomas, Nicoletta Pedemonte, John W Hanrahan, Margarida D Amaral. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR. Biochemical pharmacology. 2020 10; 180(?):114133. doi: 10.1016/j.bcp.2020.114133. [PMID: 32628927]
  • Heledd H Jarosz-Griffiths, Thomas Scambler, Chi H Wong, Samuel Lara-Reyna, Jonathan Holbrook, Fabio Martinon, Sinisa Savic, Paul Whitaker, Christine Etherington, Giulia Spoletini, Ian Clifton, Anil Mehta, Michael F McDermott, Daniel Peckham. Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis. eLife. 2020 03; 9(?):. doi: 10.7554/elife.54556. [PMID: 32118580]
  • Giulia Amico, Chiara Brandas, Oscar Moran, Debora Baroni. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors. International journal of molecular sciences. 2019 Nov; 20(21):. doi: 10.3390/ijms20215463. [PMID: 31683989]
  • Jane C Davies, Samuel M Moskowitz, Cynthia Brown, Alexander Horsley, Marcus A Mall, Edward F McKone, Barry J Plant, Dario Prais, Bonnie W Ramsey, Jennifer L Taylor-Cousar, Elizabeth Tullis, Ahmet Uluer, Charlotte M McKee, Sarah Robertson, Rebecca A Shilling, Christopher Simard, Fredrick Van Goor, David Waltz, Fengjuan Xuan, Tim Young, Steven M Rowe. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. The New England journal of medicine. 2018 10; 379(17):1599-1611. doi: 10.1056/nejmoa1807119. [PMID: 30334693]
  • Elena K Schneider. Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor. Drug metabolism letters. 2018; 12(1):71-74. doi: 10.2174/1872312812666180328105259. [PMID: 29595119]
  • Steven M Rowe, Alan S Verkman. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harbor perspectives in medicine. 2013 Jul; 3(7):. doi: 10.1101/cshperspect.a009761. [PMID: 23818513]